Diligence memo · auto-generated · as of July 2, 2026
3D Bio Holdings, Inc.
3D Bio Holdings, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
3D Bio Holdings, Inc. operates in Biotechnology, based in Brooklyn.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
3D Bio Holdings, Inc. has raised $8.4M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.0M on 2019-02-05.
Most recent recorded round closed around 2019-02-05.
Valuation (modeled)modeled
Provath models 3D Bio Holdings, Inc. at approximately $182M (range $5.5M–$989M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.01× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era. Within the normal band (101% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 7 months.
Last raise 7.4 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 53% of Biotechnology peers (4293 compared).
Modeled value ranks above 71% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.